Brief: Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing Ht-001 Oncology Trial Toward Multi-Country Site Activation
15/01/2026 13:19
Jan 15 (Reuters) - Hoth Therapeutics Inc HOTH.O: HOTH THERAPEUTICS REACHES KEY EU REGULATORY INFLECTION POINT ADVANCING HT-001 ONCOLOGY TRIAL TOWARD MULTI-COUNTRY SITE ACTIVATION HOTH THERAPEUTICS : COUNTRY-SPECIFIC PART II REGULATORY DECISIONS IN HUNGARY, SPAIN, & POLAND ARE EXPECTED BY JAN 19, 2026 Source text: ID:nPn7fPY8Ja Further company coverage: HOTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket One
See all newsBrief: Rocket One Signs AI Chip Development Agreement Targeting Ultra-Low-Power Magnetic Computing
Brief: Rocket One Signs Agreement To Advance Nanomagnetic Ai Chip Technology And Device Prototyping
Brief: Rocket One Signs Patent License Agreement With U.S. Air Force For Technology Designed To Capture And Neutralize Hostile Drones
Brief: Rocket One To Buy 100% Ownership Of Tracer Drone Technologies
Brief: Rocket One And Nasa Reach Agreement To Advance Space Ai Technology